Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.68 |
| ▸ | TP53 | P04637 | 4/20 | 0.68 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064155 | 0.91 | TRPA1 (1.00) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL3787737 | 0.86 | TRPA1 (0.80) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL15394742 | 0.85 | TRPA1 (0.78) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL10114054 | 0.85 | RXFP1 (0.78) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL20079684 | 0.85 | TRPA1 (0.78) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL10114021 | 0.84 | TRPA1 (0.80) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL10130857 | 0.84 | TRPA1 (0.77) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL3826453 | 0.84 | TRPA1 (0.77) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL10113830 | 0.84 | TRPA1 (0.77) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL4533692 | 0.84 | RXFP1 (0.78) | TRPA1RXFP1TP53PORCNTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372350-A1 | ASTROCYTIC TRPA1 CHANNEL INHIBITION AS A NOVEL NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE | UNIVERSITE GRENOBLE ALPES (FR) | 2023-11-23 | — | — | US | claimed |
| CN-114903995-B | Application of TRPA1 ion channel as drug target in amide herbicide poisoning | 中国人民解放军军事科学院军事医学研究院 | 2023-07-28 | — | — | CN | claimed |
| EP-4213823-A1 | ASTROCYTIC TRPA1 CHANNEL INHIBITION AS A NOVEL NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE | Université Grenoble Alpes (FR) | 2023-07-26 | — | — | EP | claimed |
| CN-116437920-A | Astrocyte TRPA1 channel inhibition as a novel neuroprotective therapeutic target for the precursor phase of Alzheimer's disease | 格勒诺布尔大学 | 2023-07-14 | — | — | CN | claimed |
| CN-114903995-A | Application of TRPA1 ion channel as drug target in amide herbicide poisoning | 中国人民解放军军事科学院军事医学研究院 | 2022-08-16 | — | — | CN | claimed |
| WO-2022058946-A1 | ASTROCYTIC TRPA1 CHANNEL INHIBITION AS A NOVEL NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE | UNIVERSITÉ GRENOBLE ALPES (FR) | 2022-03-24 | — | — | WO | claimed |
| US-20250241356-A1 | ORAL COMPOSITION COMPRISING RECEPTOR MODULATOR | DANIEL MICHAEL S (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250064846-A1 | TREATMENT AND PREVENTION OF TRIGEMINAL NEURALGIA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-02-27 | — | — | US | disclosed |
| US-20240285623-A1 | TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE RETINAL DISEASES | FLONEXT S.R.L. (IT) | 2024-08-29 | — | — | US | disclosed |
| EP-4351540-A1 | TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE RETINAL DISEASES | Flonext S.r.l. (IT) | 2024-04-17 | — | — | EP | disclosed |
| CN-117460501-A | TRPA1 channel antagonist compounds for degenerative retinal diseases | 弗洛内克斯特(股份)责任有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117180431-A | Application of TRPA1 ion channel as drug target in amide herbicide poisoning | 中国人民解放军军事科学院军事医学研究院 | 2023-12-08 | — | — | CN | disclosed |
| US-20230372350-A1 | ASTROCYTIC TRPA1 CHANNEL INHIBITION AS A NOVEL NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE | UNIVERSITE GRENOBLE ALPES (FR) | 2023-11-23 | — | — | US | disclosed |
| US-20110151018-A1 | METHODS OF INSECT CONTROL | BRANDEIS UNIVERSITY (US) | 2011-06-23 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110151018-A1 | METHODS OF INSECT CONTROL | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885RXFP1 2802/4885TP53 4822/4885 |
| US-20230372350-A1 | ASTROCYTIC TRPA1 CHANNEL INHIBITION AS A NOVEL NEUROPROTECTIVE THERAPEUTIC TARGET IN THE PRODROMAL PHASES OF ALZHEIMER'S DISEASE | TRPA1, APP, TRPV2 | TRPA1 1/4885RXFP1 789/4885TP53 1974/4885 |
| US-20250064846-A1 | TREATMENT AND PREVENTION OF TRIGEMINAL NEURALGIA | TRPA1, TRPV1, TRPV3 | TRPA1 1/4885RXFP1 1225/4885TP53 4757/4885 |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | TRPA1 59/4885RXFP1 611/4885TP53 4400/4885 |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885RXFP1 33/4885TP53 4573/4885 |
| US-20240285623-A1 | TRPA1 CHANNEL ANTAGONIST COMPOUND FOR USE IN DEGENERATIVE RETINAL DISEASES | TRPA1, TRPM2, TRPV1 | TRPA1 1/4885RXFP1 353/4885TP53 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.